MX2016015551A - Composicion farmaceutica que comprende compuesto de pirazina-carboxamida como ingrediente activo. - Google Patents

Composicion farmaceutica que comprende compuesto de pirazina-carboxamida como ingrediente activo.

Info

Publication number
MX2016015551A
MX2016015551A MX2016015551A MX2016015551A MX2016015551A MX 2016015551 A MX2016015551 A MX 2016015551A MX 2016015551 A MX2016015551 A MX 2016015551A MX 2016015551 A MX2016015551 A MX 2016015551A MX 2016015551 A MX2016015551 A MX 2016015551A
Authority
MX
Mexico
Prior art keywords
inhibiting effect
cancers
jak3
itk
btk
Prior art date
Application number
MX2016015551A
Other languages
English (en)
Inventor
Sakagami Hideki
Tanaka Hiroaki
Konagai Satoshi
Yamamoto Hiroko
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2016015551A publication Critical patent/MX2016015551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una composición farmacéutica para tratar el cáncer en el cual están implicadas una o más quinasas BTK, JAK3 e ITK. Los presentes inventores estudiaron compuestos que tienen un efecto inhibidor de BTK, un efecto inhibidor de JAK3 y un efecto inhibidor de ITK, y confirmaron que un compuesto de pirazina carboxamida específico tiene el efecto inhibidor de BTK, el efecto inhibidor de JAK3 y el efecto inhibidor de ITK y que una composición farmacéutica que comprende el compuesto como ingrediente activo tiene un efecto terapéutico sobre el cáncer en el cual está implicada una o más quinasas de BTK, JAK3 e ITK, en otro aspecto, cáncer en el cual se sobreexpresa o activa la BTK, en otro aspecto, cáncer en el cual se activa la señal del receptor de células B, aún en otro aspecto, un cáncer en el cual se activa-muta o activa la JAK3 y aún en otro aspecto, el cáncer en el cual se activa la ITK, completando de este modo la presente invención.
MX2016015551A 2014-05-28 2015-05-27 Composicion farmaceutica que comprende compuesto de pirazina-carboxamida como ingrediente activo. MX2016015551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014109952 2014-05-28
PCT/JP2015/065154 WO2015182628A1 (ja) 2014-05-28 2015-05-27 ピラジンカルボキサミド化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
MX2016015551A true MX2016015551A (es) 2017-03-23

Family

ID=54698952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015551A MX2016015551A (es) 2014-05-28 2015-05-27 Composicion farmaceutica que comprende compuesto de pirazina-carboxamida como ingrediente activo.

Country Status (15)

Country Link
US (1) US20170196859A1 (es)
EP (1) EP3150206A1 (es)
JP (1) JPWO2015182628A1 (es)
KR (1) KR20170005820A (es)
CN (1) CN106456636A (es)
AU (1) AU2015266552A1 (es)
CA (1) CA2949028A1 (es)
EA (1) EA201692479A1 (es)
IL (1) IL249010A0 (es)
MA (1) MA39908A (es)
MX (1) MX2016015551A (es)
PH (1) PH12016502313A1 (es)
SG (1) SG11201609837WA (es)
TW (1) TW201625254A (es)
WO (1) WO2015182628A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6112530B2 (ja) * 2015-04-27 2017-04-12 アステラス製薬株式会社 安定化されてなる医薬組成物
JP2019014653A (ja) * 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
US20190282569A1 (en) * 2016-10-26 2019-09-19 Astellas Pharma Inc. Stable pharmaceutical composition
EP4370506A1 (en) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986640C (en) * 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
SG186378A1 (en) * 2010-06-23 2013-01-30 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
CN104080774B (zh) * 2012-01-17 2017-02-22 安斯泰来制药株式会社 吡嗪甲酰胺化合物

Also Published As

Publication number Publication date
AU2015266552A1 (en) 2016-12-01
JPWO2015182628A1 (ja) 2017-04-20
CN106456636A (zh) 2017-02-22
EP3150206A1 (en) 2017-04-05
EA201692479A1 (ru) 2017-03-31
WO2015182628A1 (ja) 2015-12-03
IL249010A0 (en) 2017-01-31
MA39908A (fr) 2015-12-03
TW201625254A (zh) 2016-07-16
SG11201609837WA (en) 2016-12-29
US20170196859A1 (en) 2017-07-13
KR20170005820A (ko) 2017-01-16
PH12016502313A1 (en) 2017-02-13
CA2949028A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
PH12016501578A1 (en) Pharmaceutical compounds
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12016501962B1 (en) Macrocyclic pyridine derivatives
PH12016501963A1 (en) Macrocyclic pyrimidine derivatives
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
PH12016501527B1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
PH12016502313A1 (en) Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
PT3279210T (pt) Péptido com atividade anticancerígena, composição farmacêutica e composição de suplementos alimentares para prevenção e tratamento do cancro, ambos os quais contêm o mesmo ingrediente ativo
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
PH12017501334B1 (en) 3,5-diaminopyrazole kinase inhibitors
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
MX2017007648A (es) Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.